Priority Review Voucher Eligibility List Gains Three Tropical Diseases
Executive Summary
US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.
You may also be interested in...
Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.
Sickle Cell Disease Should Qualify For Tropical Disease Priority Review Voucher, Group Says
In citizen petition to US FDA, rare diseases nonprofit group asks agency to add sickle cell disease to its tropical disease PRV list since the disease predominantly impacts those who live in Africa and the African American population in the US.
Neglected Tropical Disease Designation Rejected For First Time By US FDA
Pneumocystis pneumonia was determined to not meet criteria for a neglected tropical disease that could win sponsors of a new treatment a priority review voucher; FDA made four other diseases eligible.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: